^
Association details:
| Biomarker: | SPECC1L-RET fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | vepafestinib (TAS0953/HM06) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases
Published date:
05/26/2022
Excerpt:
We injected ECLC5 (NSCLC cell line, TRIM33-RET) and HMSC-RET (immortalized human mesenchymal stem cells in which SPECCL1-RET was introduced by CRISPR-Cas9 genomic engineering, sarcoma model) cells... TAS0953/HM06 was superior to selpercatinib at inhibiting growth of ECLC5 (p < 0.0001) and HMSC-RET (p = 0.0005) brain xenograft tumors, and increasing survival of tumor-bearing animals (ECLC5: TAS0953/HM06 139±0.5 days, selpercatinib 95+2.3 days, p = 0.002; HMSC-RET: TAS0953/HM06 41± 2.2 days, selpercatinib 20±3 days, p = 0.0001).
DOI:
10.1200/JCO.2022.40.16_suppl.2024
